Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab820
Abstract: Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels… read more here.
Keywords: every weeks; apolipoprotein iii; moderate hypertriglyceridaemia; risk ... See more keywords
A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides
Sign Up to like & getrecommendations! Published in 2020 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aaw7905
Abstract: An apolipoprotein C-II peptide mimetic for the treatment of hypertriglyceridemia activates lipoprotein lipase and blocks apolipoprotein C-III. How low can you go? People with elevated plasma triglycerides face increased risk of cardiovascular disease. Wolska et… read more here.
Keywords: d6pv; apoc; plasma triglycerides; apolipoprotein iii ... See more keywords
Cardiovascular Disease Risk in Children With Chronic Kidney Disease: Impact of Apolipoprotein C-II and Apolipoprotein C-III
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2021.706323
Abstract: Cardiovascular disease (CVD) is an evolving process that begins in the early stages of chronic kidney disease (CKD) in children. Several surrogate markers, such as ambulatory blood pressure monitoring (ABPM), left ventricular (LV) mass, and… read more here.
Keywords: chronic kidney; disease; apolipoprotein iii; cardiovascular disease ... See more keywords